Grant: Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
McMaster University
$105,000.00
Catechins as Adjuvants in the Treatment of Alzheimer's Disease: Enhancing the Response of Microglia to Amyloid Beta
FY 2017-18
Summary
One of the main causes of neuronal death in the brain of Alzheimer's Disease (AD) patients is the formation of toxic assemblies of the amyloid beta protein. In healthy individuals, amyloid beta mostly remains as monomers. However, genetic mutations and aging cause amyloid beta monomers to grow into larger ensembles or oligomers that are toxic to cells. One particular group of cells that are affected by the amyloid beta oligomers are microglia, "spider-like" cells that scavenge their environment and clear harmful factors. The depression of the protective effect of microglial cells by amyloid beta oligomers in AD is one of the main mechanisms through which amyloid beta self-association leads to neuronal death. Hence, amyloid beta aggregation inhibitors provide a potential therapeutic option to restore healthy microglial cells in AD patients. One such inhibitor is the green tea extract epigallocatechin gallate (EGCG). We have recently shown that EGCG remodels existing toxic amyloid beta oligomers into non-toxic structures by coating the surface of these oligomers and inhibiting their growth. However, it is still unclear which amyloid beta oligomer-cell interactions are down-regulated upon addition of EGCG. Understanding this is critical for turning EGCG into a viable drug-like molecule. We speculate that the EGCG-induced coating prevents the interaction of amyloid beta with healthy cells, such as microglia, and arrests its toxic effects. To test this hypothesis, we plan to monitor the interaction of amyloid beta oligomers with microglia in the absence and presence of EGCG, using NMR and fluorescence spectroscopies combined with confocal microscopy. This study will provide a better understanding of the EGCG inhibitor mechanism and will facilitate the development of new inhibitors of amyloid beta aggregation.
Department
Program
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
383278
Name
Ahmed Rashik
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Catechins as Adjuvants in the Treatment of Alzheimer's Disease: Enhancing the Response of Microglia to Amyloid Beta
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Frederick Banting and Charles Best Canada Graduate Scholarships
Keyworddelim
Alzheimer'S Disease; Amyloid Beta; Catechins; Egcg; Microglia; Neurodegenerative Disorder; Nmr
Abstract
One of the main causes of neuronal death in the brain of Alzheimer's Disease (AD) patients is the formation of toxic assemblies of the amyloid beta protein. In healthy individuals, amyloid beta mostly remains as monomers. However, genetic mutations and aging cause amyloid beta monomers to grow into larger ensembles or oligomers that are toxic to cells. One particular group of cells that are affected by the amyloid beta oligomers are microglia, "spider-like" cells that scavenge their environment and clear harmful factors. The depression of the protective effect of microglial cells by amyloid beta oligomers in AD is one of the main mechanisms through which amyloid beta self-association leads to neuronal death. Hence, amyloid beta aggregation inhibitors provide a potential therapeutic option to restore healthy microglial cells in AD patients. One such inhibitor is the green tea extract epigallocatechin gallate (EGCG). We have recently shown that EGCG remodels existing toxic amyloid beta oligomers into non-toxic structures by coating the surface of these oligomers and inhibiting their growth. However, it is still unclear which amyloid beta oligomer-cell interactions are down-regulated upon addition of EGCG. Understanding this is critical for turning EGCG into a viable drug-like molecule. We speculate that the EGCG-induced coating prevents the interaction of amyloid beta with healthy cells, such as microglia, and arrests its toxic effects. To test this hypothesis, we plan to monitor the interaction of amyloid beta oligomers with microglia in the absence and presence of EGCG, using NMR and fluorescence spectroscopies combined with confocal microscopy. This study will provide a better understanding of the EGCG inhibitor mechanism and will facilitate the development of new inhibitors of amyloid beta aggregation.
Competitiondate
201710
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Ahmed, Rashik
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~